These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 16163196)

  • 1. Mechanisms and treatment for bone metastases.
    Clines GA; Guise TA
    Clin Adv Hematol Oncol; 2004 May; 2(5):295-302. PubMed ID: 16163196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone.
    Clines GA; Guise TA
    Endocr Relat Cancer; 2005 Sep; 12(3):549-83. PubMed ID: 16172192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanisms and treatment of bone metastasis.
    Clines GA; Guise TA
    Expert Rev Mol Med; 2008 Mar; 10():e7. PubMed ID: 18321396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model.
    Yang M; Burton DW; Geller J; Hillegonds DJ; Hastings RH; Deftos LJ; Hoffman RM
    Clin Cancer Res; 2006 Apr; 12(8):2602-6. PubMed ID: 16638872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypercalcemia and bone resorption in malignancy.
    Walls J; Bundred N; Howell A
    Clin Orthop Relat Res; 1995 Mar; (312):51-63. PubMed ID: 7634618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [PTHrP and breast cancer].
    Devys A; Lortholary A; Audran M
    Bull Cancer; 2001 Nov; 88(11):1075-80. PubMed ID: 11741801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention.
    Lipton A
    J Support Oncol; 2004; 2(3):205-13; discussion 213-4, 216-7, 219-20. PubMed ID: 15328823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential role of bisphosphonates in prostate cancer.
    Oades GM; Coxon J; Colston KW
    Prostate Cancer Prostatic Dis; 2002; 5(4):264-72. PubMed ID: 12627210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo.
    Fournier PG; Daubiné F; Lundy MW; Rogers MJ; Ebetino FH; Clézardin P
    Cancer Res; 2008 Nov; 68(21):8945-53. PubMed ID: 18974139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malignancy and the skeleton.
    Mundy GR
    Horm Metab Res; 1997 Mar; 29(3):120-7. PubMed ID: 9137982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of parathyroid hormone-related peptide in hypercalcemia of malignancy and the development of osteolytic metastases.
    de Vernejoul MC
    Rev Rhum Engl Ed; 1997 Jun; 64(6 Suppl):119S-123S. PubMed ID: 9273953
    [No Abstract]   [Full Text] [Related]  

  • 12. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden.
    Le Gall C; Bellahcène A; Bonnelye E; Gasser JA; Castronovo V; Green J; Zimmermann J; Clézardin P
    Cancer Res; 2007 Oct; 67(20):9894-902. PubMed ID: 17942921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of therapeutic agents to bone to treat metastatic cancer.
    Bagi CM
    Adv Drug Deliv Rev; 2005 May; 57(7):995-1010. PubMed ID: 15876400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future treatment of bone metastases.
    Lipton A
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6305s-6308s. PubMed ID: 17062719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local effects of malignancy on bone.
    Brown SA; Clines GA; Guise TA
    Curr Opin Endocrinol Diabetes Obes; 2007 Dec; 14(6):436-41. PubMed ID: 17982348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current use of bisphosphonates in clinical oncology].
    Vrbanec D; Plestina S; Belev B; Unusić J; Pavlinić-Diminić V
    Lijec Vjesn; 1999; 121(9-10):296-301. PubMed ID: 19658372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis.
    Vessella RL; Corey E
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6285s-6290s. PubMed ID: 17062715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypercalcemia of malignancy: pathophysiology and implications for treatment.
    Theriault RL
    Oncology (Williston Park); 1993 Jan; 7(1):47-50; discussion 52-5. PubMed ID: 8420542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-bone interactions in skeletal metastasis.
    Orr FW; Sanchez-Sweatman OH; Kostenuik P; Singh G
    Clin Orthop Relat Res; 1995 Mar; (312):19-33. PubMed ID: 7634602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Similarities and differences in tumor growth, skeletal remodeling and pain in an osteolytic and osteoblastic model of bone cancer.
    Halvorson KG; Sevcik MA; Ghilardi JR; Rosol TJ; Mantyh PW
    Clin J Pain; 2006 Sep; 22(7):587-600. PubMed ID: 16926574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.